Four of the six patients who were vaccinated during 25 months there were no recurrences of melanoma.
American, German and Austrian oncologists have proven that they tested a personalized cancer vaccine are safe and clinically effective for the prevention of melanoma. Two related studies published in the journal Nature.
The first publication of American scientists report on the results of the first phase clinical trial of a vaccine aimed at 20 personalized neoantigens associated with skin cancer. Four of the six patients who were vaccinated during 25 months there were no recurrences of melanoma.
In the second publication of the German and Austrian authors report the first of its kind application of a personalized approach to vaccination based on RNA, which aimed at the destruction of 13 patients, melanoma patients, neoepitopes. In eight patients after 23 months after vaccination, the tumor disappeared.
Experts plan to proceed to the second phase of clinical trials of vaccines, and to determine their effectiveness in combating other types of cancer.
© 2017, paradox. All rights reserved.
